Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Disparities in Guideline-Recommended Statin Use for Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and Gender
David A. Frank, Amber E. Johnson, Leslie R. M. Hausmann, et al.
Annals of Internal Medicine (2023) Vol. 176, Iss. 8, pp. 1057-1066
Open Access | Times Cited: 19

Showing 19 citing articles:

Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association
Sadiya S. Khan, Josef Coresh, Michael Pencina, et al.
Circulation (2023) Vol. 148, Iss. 24, pp. 1982-2004
Closed Access | Times Cited: 190
Projected Changes in Statin and Antihypertensive Therapy Eligibility With the AHA PREVENT Cardiovascular Risk Equations
James A. Diao, Ivy Shi, Venkatesh L. Murthy, et al.
JAMA (2024) Vol. 332, Iss. 12, pp. 989-989
Closed Access | Times Cited: 27
Racial and Ethnic Disparities in Primary Prevention of Cardiovascular Disease
Mohammad Ali, Hadjer Nacer, Claire Lawson, et al.
Canadian Journal of Cardiology (2024) Vol. 40, Iss. 6, pp. 1016-1030
Open Access | Times Cited: 10
Early-onset atherosclerotic cardiovascular disease
Idine Mousavi, John Suffredini, Salim S. Virani, et al.
European Journal of Preventive Cardiology (2024)
Open Access | Times Cited: 4
Trends in Co-morbid Dementia and Chronic Kidney Disease
Milda R. Saunders, Mingyu Qi, Elbert S. Huang, et al.
Journal of General Internal Medicine (2025)
Closed Access
SLCO1B1 Functional Variants, Bilirubin, Statin‐Induced Myotoxicity, and Recent Sub‐Saharan African Ancestry: A Precision Medicine Health Equity Study
Tanushree Haldar, Mark Kvale, Jia Yang, et al.
Clinical Pharmacology & Therapeutics (2025)
Open Access
Advancement of the Implementation of Evidence-based Therapies for Cardiovascular-Kidney-Metabolic Conditions: A Multi-Stakeholder Perspective
Nkiru Osude, Harriette Van Spall, Hayden B. Bosworth, et al.
American Heart Journal (2025)
Closed Access
Disparities in statin use following identification of coronary artery calcium
Charlotte C. Ellberg, Kavenpreet Bal, Edward Duran, et al.
American Journal of Preventive Cardiology (2025), pp. 100990-100990
Open Access
Proton Pump Inhibitor Use Exceeding the U.S. Food and Drug Administration Approved Treatment Duration for Patients With Peptic Ulcer Disease: A Retrospective Cohort Study
Jordan Villars, Timothy S. Anderson, Jonathan G. Yabes, et al.
Pharmacoepidemiology and Drug Safety (2025) Vol. 34, Iss. 5
Open Access
ChatGPT Exhibits Gender and Racial Biases in Acute Coronary Syndrome Management
Angela Zhang, Mert Yüksekgönül, Joshua Guild, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 7
LGBTQ+ cardiovascular health equity: a brief review
Jason A. Bonomo, Kate Luo, Jorge Ramallo
Frontiers in Cardiovascular Medicine (2024) Vol. 11
Open Access | Times Cited: 2
Inequities in atherosclerotic cardiovascular disease prevention
Sofia Gomez, Ramzi Dudum, Fátima Rodríguez
Progress in Cardiovascular Diseases (2024) Vol. 84, pp. 43-50
Closed Access | Times Cited: 2
Eliminating Health Disparities in Atrial Fibrillation, Heart Failure, and Dyslipidemia: A Path Toward Achieving Pharmacoequity
Krunal Amin, Garrett Bethel, Larry R. Jackson, et al.
Current Atherosclerosis Reports (2023) Vol. 25, Iss. 12, pp. 1113-1127
Closed Access | Times Cited: 4
Patterns and gaps in guideline-directed statin use for atherosclerotic cardiovascular disease by race and ethnicity
Ashish Sarraju, Xiaowei Yan, Qiwen Huang, et al.
American Journal of Preventive Cardiology (2024) Vol. 17, pp. 100647-100647
Open Access | Times Cited: 1
What are we missing to gain the battle against cardiovascular diseases?
Harshitha Shanmugam, Piero Portincasa, Agostino Di Ciaula
European Heart Journal (2024)
Open Access | Times Cited: 1
Million Hearts Cardiovascular Disease Risk Reduction Model
Gabriel S. Tajeu, Karen E. Joynt Maddox, LaPrincess C. Brewer
JAMA (2023) Vol. 330, Iss. 15, pp. 1430-1430
Open Access | Times Cited: 3
Effectiveness of HMG-CoA reductase inhibitors on inflammation and metabolic markers in the US-Mexico border Hispanic population
Phong Nguyen, Vishwajeet Singh, Vikram Thakur, et al.
Journal of Investigative Medicine (2024) Vol. 72, Iss. 4, pp. 359-369
Closed Access
Atherosclerotic Cardiovascular Disease Primary and Secondary Prevention in Latino Subgroups
Jorge Kaufmann, Miguel A. Mariño, Jennifer Lucas, et al.
Journal of General Internal Medicine (2024) Vol. 39, Iss. 11, pp. 2041-2050
Closed Access
SLCO1B1functional variants and statin-induced myopathy in people with recent genealogical ancestors from Africa: a population-based real-world study
Sook Wah Yee, Tanushree Haldar, Mark Kvale, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Sex, Ethnicity and Language Differences in Statin Prescribing in Community Health Center Patients
Tahlia Hodes, Miguel A. Mariño, Jorge Kaufmann, et al.
American Journal of Preventive Cardiology (2024) Vol. 20, pp. 100873-100873
Open Access
Page 1

Scroll to top